The Search for Biomarkers in Alzheimer's Disease
BACKGROUND: As population demographic shift and the number of individuals with Alzheimer Disease (AD) continue to increase, the challenge is to develop targeted, effective treatments and our ability to recognize early symptoms. In view of this, the need for specific AD biomarker is crucial. CONTENT:...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Secretariat of The Indonesian Biomedical Journal
2010-04-01
|
| Series: | Indonesian Biomedical Journal |
| Online Access: | http://inabj.org/index.php/ibj/article/view/107 |
| _version_ | 1818366327557980160 |
|---|---|
| author | Anna Meiliana Andi Wijaya |
| author_facet | Anna Meiliana Andi Wijaya |
| author_sort | Anna Meiliana |
| collection | DOAJ |
| description | BACKGROUND: As population demographic shift and the number of individuals with Alzheimer Disease (AD) continue to increase, the challenge is to develop targeted, effective treatments and our ability to recognize early symptoms. In view of this, the need for specific AD biomarker is crucial. CONTENT: In recent years it has become evident that CSF concentrations of some brain-specific proteins are related to underlying disease pathogenesis and may therefore aid clinical investigation. Among several, we have focused on three candidates that have been suggested to fulfil the requirements for biomarkers of AD: β-amyloid 42 (Aβ42), total Tau (T-tau) and tau phosphorylated at various epitopes (P-tau). An increasing number of studies suggest that supplementary use of these CSF markers, preferably in combination, adds to the accuracy of an AD diagnosis. More recently visinin-like protein (VLP-1), a marker for neuronal cell injury has been studied. CSF VLP-1 concentrations were 50% higher in AD patients than in the control population. SUMMARY: The number of studies aimed at the identification of new biomarkers for AD is expected to increase rapidly, not only because of the increasing insights into the pathological mechanisms underlying this disease, but also because new therapies have been developed or are under consideration now, which warrant an early and specific diagnosis for effective treatment of the patients. KEYWORDS: dementia, amyloid plaque, neurofibrillary tangels, amyloid β-peptide 42 (Aβ42), total tau (T-tau), phosphorylated tau (P-tau), visinin–like protein 1 (VLP-1). |
| first_indexed | 2024-12-13T22:34:24Z |
| format | Article |
| id | doaj.art-9bed1071ddf34a1594f2a99e20487a6e |
| institution | Directory Open Access Journal |
| issn | 2085-3297 2355-9179 |
| language | English |
| last_indexed | 2024-12-13T22:34:24Z |
| publishDate | 2010-04-01 |
| publisher | Secretariat of The Indonesian Biomedical Journal |
| record_format | Article |
| series | Indonesian Biomedical Journal |
| spelling | doaj.art-9bed1071ddf34a1594f2a99e20487a6e2022-12-21T23:29:01ZengSecretariat of The Indonesian Biomedical JournalIndonesian Biomedical Journal2085-32972355-91792010-04-012142510.18585/inabj.v2i1.10799The Search for Biomarkers in Alzheimer's DiseaseAnna Meiliana0Andi Wijaya1Post Graduate Program in Clinical Biochemistry, Hasanuddin University Jl. Perintis Kemerdekaan Km.10, MakassarPost Graduate Program in Clinical Biochemistry, Hasanuddin University Jl. Perintis Kemerdekaan Km.10, MakassarBACKGROUND: As population demographic shift and the number of individuals with Alzheimer Disease (AD) continue to increase, the challenge is to develop targeted, effective treatments and our ability to recognize early symptoms. In view of this, the need for specific AD biomarker is crucial. CONTENT: In recent years it has become evident that CSF concentrations of some brain-specific proteins are related to underlying disease pathogenesis and may therefore aid clinical investigation. Among several, we have focused on three candidates that have been suggested to fulfil the requirements for biomarkers of AD: β-amyloid 42 (Aβ42), total Tau (T-tau) and tau phosphorylated at various epitopes (P-tau). An increasing number of studies suggest that supplementary use of these CSF markers, preferably in combination, adds to the accuracy of an AD diagnosis. More recently visinin-like protein (VLP-1), a marker for neuronal cell injury has been studied. CSF VLP-1 concentrations were 50% higher in AD patients than in the control population. SUMMARY: The number of studies aimed at the identification of new biomarkers for AD is expected to increase rapidly, not only because of the increasing insights into the pathological mechanisms underlying this disease, but also because new therapies have been developed or are under consideration now, which warrant an early and specific diagnosis for effective treatment of the patients. KEYWORDS: dementia, amyloid plaque, neurofibrillary tangels, amyloid β-peptide 42 (Aβ42), total tau (T-tau), phosphorylated tau (P-tau), visinin–like protein 1 (VLP-1).http://inabj.org/index.php/ibj/article/view/107 |
| spellingShingle | Anna Meiliana Andi Wijaya The Search for Biomarkers in Alzheimer's Disease Indonesian Biomedical Journal |
| title | The Search for Biomarkers in Alzheimer's Disease |
| title_full | The Search for Biomarkers in Alzheimer's Disease |
| title_fullStr | The Search for Biomarkers in Alzheimer's Disease |
| title_full_unstemmed | The Search for Biomarkers in Alzheimer's Disease |
| title_short | The Search for Biomarkers in Alzheimer's Disease |
| title_sort | search for biomarkers in alzheimer s disease |
| url | http://inabj.org/index.php/ibj/article/view/107 |
| work_keys_str_mv | AT annameiliana thesearchforbiomarkersinalzheimersdisease AT andiwijaya thesearchforbiomarkersinalzheimersdisease AT annameiliana searchforbiomarkersinalzheimersdisease AT andiwijaya searchforbiomarkersinalzheimersdisease |